Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C.
Lawitz E, Gruener D, Marbury T, Hill J, Webster L, Hassman D, Nguyen AH, Pflanz S, Mogalian E, Gaggar A, Massetto B, Subramanian GM, McHutchison JG, Jacobson IM, Freilich B, Rodriguez-Torres M. Lawitz E, et al. Among authors: marbury t. Antivir Ther. 2015;20(7):699-708. doi: 10.3851/IMP2845. Epub 2014 Aug 8. Antivir Ther. 2015. PMID: 25105516 Clinical Trial.
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.
Nettles RE, Gao M, Bifano M, Chung E, Persson A, Marbury TC, Goldwater R, DeMicco MP, Rodriguez-Torres M, Vutikullird A, Fuentes E, Lawitz E, Lopez-Talavera JC, Grasela DM. Nettles RE, et al. Hepatology. 2011 Dec;54(6):1956-65. doi: 10.1002/hep.24609. Hepatology. 2011. PMID: 21837752 Clinical Trial.
GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study.
Rodriguez-Torres M, Glass S, Hill J, Freilich B, Hassman D, Di Bisceglie AM, Taylor JG, Kirby BJ, Dvory-Sobol H, Yang JC, An D, Stamm LM, Brainard DM, Kim S, Krefetz D, Smith W, Marbury T, Lawitz E. Rodriguez-Torres M, et al. Among authors: marbury t. J Viral Hepat. 2016 Aug;23(8):614-22. doi: 10.1111/jvh.12527. Epub 2016 Mar 9. J Viral Hepat. 2016. PMID: 26957110 Clinical Trial.
Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy.
Lawitz E, Godofsky E, Rouzier R, Marbury T, Nguyen T, Ke J, Huang M, Praestgaard J, Serra D, Evans TG. Lawitz E, et al. Among authors: marbury t. Antiviral Res. 2011 Mar;89(3):238-45. doi: 10.1016/j.antiviral.2011.01.003. Epub 2011 Jan 19. Antiviral Res. 2011. PMID: 21255610 Clinical Trial.
The Safety and Antiviral Activity of BZF961 with or without Ritonavir in Patients Infected with Hepatitis C Virus: A Randomized, Multicenter Trial.
Lawitz E, Bidair M, Marbury T, Jones CT, Barve A, Magnusson B, Barkan DT, Bodendorf U, Bracken K, Canino E, Chen D, Dabovic K, Heimbach T, Ison M, Jones CL, Kovacs SJ, Lakshman JP, Li B, Raman P, Steiner-Swiat R, Thohan S, Wong KA, Zhong W, Colvin RA. Lawitz E, et al. Among authors: marbury t. Clin Ther. 2018 Sep;40(9):1567-1581.e4. doi: 10.1016/j.clinthera.2018.07.019. Epub 2018 Sep 2. Clin Ther. 2018. PMID: 30185394 Clinical Trial.
196 results